Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN
Year: 2015
Type: article
Abstract: Severe GN involves local neutrophil extracellular trap (NET) formation. We hypothesized a local cytotoxic effect of NET-related histone release in necrotizing GN. In vitro, histones from calf thymus or histones released by neutrophils undergoing NETosis killed glomerular endothelial cells, podocytes, and parietal epithelial cells in a dose-dependent manner. Histone-neutralizing agents such as antihistone IgG, activated protein C, or heparin prevented this effect. Histone toxicity on glomeruli ex vivo was Toll-like receptor 2/4 dependent, and lack of TLR2/4 attenuated histone-induced renal thrombotic microangiopathy and glomerular necrosis in mice. Anti-glomerular basement membrane GN involved NET formation and vascular necrosis, whereas blocking NET formation by peptidylarginine inhibition or preemptive anti-histone IgG injection significantly reduced all aspects of GN (i.e., vascular necrosis, podocyte loss, albuminuria, cytokine induction, recruitment or activation of glomerular leukocytes, and glomerular crescent formation). To evaluate histones as a therapeutic target, mice with established GN were treated with three different histone-neutralizing agents. Anti-histone IgG, recombinant activated protein C, and heparin were equally effective in abrogating severe GN, whereas combination therapy had no additive effects. Together, these results indicate that NET-related histone release during GN elicits cytotoxic and immunostimulatory effects. Furthermore, neutralizing extracellular histones is still therapeutic when initiated in established GN.
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Keywords: neutrophil extracellular traps, extracellular histones, glomerulonephritis, glomerular necrosis, thrombotic microangiopathy, TLR2/4, podocyte injury, parietal epithelial cells, glomerular endothelial cells, activated protein C, heparin, Goodpasture's syndrome, albuminuria, glomerular crescents
Open Access status: green
Funder: Eli Lilly and Company
OpenAlex ID: W2137698235
